US FDA approves Erbitux

Published: 8-Nov-2011

For treating late-stage head and neck cancer


The US FDA has approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer.

Combined with chemotherapy, Erbitux extended the lives of those receiving the treatment combination compared with those receiving chemotherapy alone.

Erbitux already is FDA-approved for certain types of colon cancer, and has been approved since 2006 for treatment of non-metastatic head and neck cancer in combination with radiation therapy (first-line) or as a single agent (following standard treatment).

Erbitux is co-marketed by Bristol-Myers Squibb and Eli Lilly.

The FDA first approved Erbitux in 2004 to treat Epidermal Growth Factor Receptor (EGFR)-positive late-stage colon cancer after patients stopped responding to chemotherapy.

See more

You may also like

Regulatory

Oncolytics Biotech announces positive clinical data for metastatic colorectal cancer trial

Read more
The latest results could accelerate the company's path to registration after the FDA's Breakthrough Therapy designations created momentum for companies advancing pioneering oncology platforms

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Regulatory

Oncolytics Biotech announces positive clinical data for metastatic colorectal cancer trial

The latest results could accelerate the company's path to registration after the FDA's Breakthrough Therapy designations created momentum for companies advancing pioneering oncology platforms
Regulatory

FDA to get foreign manufacturing inspections "back on track" with new inspection scheme

The inspection scheme means that foreign pharmaceutical and medical product manufacturers will be subject to unannounced inspections by the US regulator
Regulatory

Sanofi's Novolog biosimilar Merilog gets the FDA green light

The biosimilar improves glycaemic control in diabetic patients by lowering blood sugar spikes, and is the first fast-acting insulin analog to be approved in the US
Manufacturing

The US FDA bans colour additive Red No. 3 from use in oral solid dosage forms

Ingestible drug manufacturers will have until January 18, 2028 to reformulate their products, as Red No. 3 has been linked to cancer in male rats
Regulatory

AstraZeneca's Imfinzi granted priority review and BTD by the US FDA for SCLC

The therapeutic significantly improved PFS and OS in patients with limited-stage small cell lung cancer in the Phase III ADRIATIC trial
Manufacturing

FDA releases guidance to clarify guidelines for 'remanufacturing' devices that need maintenance or repair

The guidelines includes information on reusable product labelling, what it classifies as 'remanufacturing' and how companies can ensure products follow guidelines after multiple uses
Manufacturing

GSK and Pistoia Alliance announce laboratory tech to improve reproducibility

Founded by Pistoia Alliance and now implemented at GSK, the Methods Hub is a digital tool that enables the instant transfer and overlaying of analytical methods
Subscribe now